We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Merck has exercised the option to license an investigational product called NGM313 from NGM Biopharmaceuticals under a strategic agreement signed between the companies in 2015.....